CoChat

Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Aim: The aim of this study was to evaluate the impact of patients’ characteristics on the efficacy and the safety of subcutaneous tirzepatide once-weekly in patients with uncontrolled type 2 diabetes mellitus (T2DM). Materials and Methods: This post hoc analysis of pooled SURPASS 1-5 randomized controlled trials narratively examined changes from baseline in hemoglobin A1c (HbA1c) and body weight and the proportions of patients who achieved the endpoint composite HbA1c with tirzepatide (5, 10, and 15 mg) across the following subgroups; baseline HbA1c (≥ 7.5% to ≤8.0% [≥48 ≤ 64 mmol/mol], ≥8.0% to ≤8.5% [≥64 ≤68 mmol/mol], and ≥ 8.5% to ≤9.0% [≥68 ≤75 mmol/mol]), baseline diabetes durations (≤ 5 years, 5–10 years, and ≥ 10 years), and age (non-elderly ≤ 60 years and elderly ≥ 60 years). Results: Based on diabetes duration, the mean HbA1c reduced from baseline (≥–1.87 % to ≤–2.24% [≥–20.57 to ≤–24.64 mmol/mol]) for tirzepatide 5 mg ( P = 0.308), –1.89 % to –2.43% (–20.79 to –26.73 mmol/mol) with tirzepatide 10 mg ( P = 0.015) and ≥–2.07 % to≤ –2.58 % (≥–22.77 to ≤–28.38 mmol/mol) with tirzepatide 15 mg ( P = 0.010). Similar HbA1c and body weight reductions were observed across other subgroups (baseline HbA1c and age). Conclusion: Tirzepatide was consistently efficacious and safe in the broad spectrum of patients with T2DM subgroups across the SURPASS 1-5 trials.

Overview

Integrity signals

Registry

Crossref · 10.4103/jod.jod_16_23

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 8

Metadata

Authors
Abdalla, M. A., Soyiri, I., Atkin, S., & Sathyapalan, T.
Affiliations
  • University of Hull (GB)
  • Royal College of Surgeons in Ireland - Bahrain (BH)
Corresponding author
Abdalla, Mohammed Altigani
Venue
Journal of Diabetology
Published
2023-04
Volume
14
Issue
2
Pages
65-73
ISSN
  • 2078-7685 (ISSN-L)
  • 2543-3288
OpenAlex
W4378908091
Cited by
8
References
21
Citations by year
2026: 4 · 2025: 2 · 2024: 1 · 2023: 1
FWCI
1.64
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Journal of Diabetology (publishedVersion, cc-by-nc-sa)
  • Repository@Hull (Worktribe) (University of Hull) (publishedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, type 2 diabetes, SURPASS trials, glycemic control, HbA1c reduction, weight loss, diabetes duration, baseline HbA1c, elderly patients, subgroup analysis, drug safety and efficacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials. https://app.cochat.ai/papers/10.4103/jod.jod_16_23
The paper
Abdalla, M. A., Soyiri, I., Atkin, S., & Sathyapalan, T. (2023). Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials. Journal of Diabetology. https://doi.org/10.4103/jod.jod_16_23

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.